Sponsor Directory

AbbVie clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

816

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Myelodysplastic Syndromes (MDS)
Interventions: venetoclax, azacitidine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 10
States / cities: Tucson, Arizona • Aurora, Colorado • New Haven, Connecticut + 6 more

Conditions: Hepatitis C Virus (HCV)
Interventions: Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 15
States / cities: San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more

Conditions: Healthy Volunteers
Interventions: Risankizumab Dose A, Risankizumab Dose B; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 198 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Anaheim, California • Miami, Florida • Grayslake, Illinois + 2 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 661 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 57
States / cities: Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 49 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 6
States / cities: Louisville, Kentucky • Baltimore, Maryland • Hackensack, New Jersey + 3 more

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: Venetoclax, Dexamethasone; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 21
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • New Haven, Connecticut + 18 more

Conditions: Healthy Volunteers
Interventions: ABBV-552; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 2
States / cities: Anaheim, California • Las Vegas, Nevada

Conditions: Multiple Myeloma
Interventions: Nivolumab, Elotuzumab, Pomalidomide, Dexamethasone; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 72
States / cities: Birmingham, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 65 more

Conditions: Parkinson's Disease
Interventions: ABBV-951; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more

Conditions: Acute Myeloid Leukemia (AML), Cancer
Interventions: Venetoclax, Azacitidine, Decitabine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 16
States / cities: Tempe, Arizona • Denver, Colorado • Lone Tree, Colorado + 12 more

Conditions: Ulcerative Colitis (UC)
Interventions: Ravagalimab 600 mg, Ravagalimab 300 mg; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 12
States / cities: Tucson, Arizona • Huntington Beach, California • Lakewood, California + 9 more

Conditions: ABBV-154
Interventions: ABBV-154 Dose Formulation A, ABBV-154 Dose Formulation B; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Grayslake, Illinois • Las Vegas, Nevada

About this AbbVie sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AbbVie is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AbbVie trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AbbVie clinical trials

Filter and sort this sponsor

Live official records

A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers.

A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone

A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants

An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma

Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants

About this AbbVie sponsor directory page